MA34245B1 - Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc. - Google Patents
Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.Info
- Publication number
- MA34245B1 MA34245B1 MA35387A MA35387A MA34245B1 MA 34245 B1 MA34245 B1 MA 34245B1 MA 35387 A MA35387 A MA 35387A MA 35387 A MA35387 A MA 35387A MA 34245 B1 MA34245 B1 MA 34245B1
- Authority
- MA
- Morocco
- Prior art keywords
- acc
- inhibitors
- derivatives
- bicyclic compounds
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Abstract
La présente invention concerne un composé possédant une activité inhibitrice de l'ACC. Ledit composé est utile en tant qu'agent destiné à la prophylaxie et au traitement de l'obésité, du diabète, de l'hypertension, d'une hyperlipidémie, d'une insuffisance cardiaque, de complications diabétiques, du syndrome métabolique, de la sarcopénie, du cancer et analogues, et il présente une activité supérieure. La présente invention concerne un composé représenté par la formule (I): dans laquelle chaque symbole est tel que défini dans le mémoire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010102718 | 2010-04-27 | ||
PCT/JP2011/060616 WO2011136385A1 (fr) | 2010-04-27 | 2011-04-26 | Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc. |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34245B1 true MA34245B1 (fr) | 2013-05-02 |
Family
ID=44120718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35387A MA34245B1 (fr) | 2010-04-27 | 2011-04-26 | Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc. |
Country Status (23)
Country | Link |
---|---|
US (1) | US8703758B2 (fr) |
EP (1) | EP2563765B1 (fr) |
JP (1) | JP5693611B2 (fr) |
KR (1) | KR20130094211A (fr) |
CN (1) | CN103025716B (fr) |
AR (1) | AR080969A1 (fr) |
AU (1) | AU2011246004A1 (fr) |
BR (1) | BR112012027648A2 (fr) |
CA (1) | CA2797767A1 (fr) |
CO (1) | CO6640253A2 (fr) |
CR (1) | CR20120598A (fr) |
EA (1) | EA021698B1 (fr) |
EC (1) | ECSP12012311A (fr) |
ES (1) | ES2546130T3 (fr) |
GE (1) | GEP20146178B (fr) |
MA (1) | MA34245B1 (fr) |
NZ (1) | NZ603777A (fr) |
SG (1) | SG185759A1 (fr) |
TW (1) | TW201206911A (fr) |
UA (1) | UA108102C2 (fr) |
UY (1) | UY33354A (fr) |
WO (1) | WO2011136385A1 (fr) |
ZA (1) | ZA201208895B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20140161A1 (es) | 2010-11-30 | 2014-02-19 | Takeda Pharmaceutical | Compuesto biciclico |
CA2853221A1 (fr) | 2011-10-24 | 2013-05-02 | Tohru Yamashita | Compose bicyclique |
US8530460B2 (en) * | 2011-12-19 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
US8530461B2 (en) | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
US8623860B2 (en) * | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
KR20160042089A (ko) | 2013-09-12 | 2016-04-18 | 화이자 인코포레이티드 | 심상성 여드름 치료용 아세틸-CoA 카복실라아제 억제제의 용도 |
JP6050291B2 (ja) * | 2014-08-07 | 2016-12-21 | 長谷川香料株式会社 | ソラノンの製造方法およびその合成中間体 |
JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | 9員縮合環誘導体 |
CN106636402B (zh) * | 2016-12-22 | 2020-09-15 | 中南大学湘雅医院 | 一种判断鼻咽癌放疗敏感性的分子标志物及应用 |
JP7361584B2 (ja) * | 2018-12-19 | 2023-10-16 | 高砂香料工業株式会社 | アミドの還元によるアミンの製造方法 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
CA2372840C (fr) | 1999-05-05 | 2008-07-22 | Aventis Pharma Limited | Composes bicycliques substitues |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
WO2001082925A1 (fr) | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone concentrant la melanine |
US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
EP1302462A4 (fr) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | Derives de sulfonate, procede de production et utilisation de ces derives |
ATE303178T1 (de) * | 2002-02-27 | 2005-09-15 | Pfizer Prod Inc | Acc-hemmer |
JPWO2003104230A1 (ja) | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | 二環性ピリミジン誘導体 |
RU2337682C2 (ru) | 2002-11-01 | 2008-11-10 | Такеда Фармасьютикал Компани Лимитед | Средство для профилактики или лечения невропатии |
WO2004041266A1 (fr) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Agent de controle de la fonction recepteur |
AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
EP1630152A4 (fr) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | Compose cyclique condense |
EP1669352A4 (fr) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | Derive thiazoline et utilisation |
WO2005058823A1 (fr) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Derives d'uree, processus de production correspondant et utilisation |
RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
EP1698624B1 (fr) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Derives d'acide phenylpropanoique |
WO2005087710A1 (fr) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Dérivé de l'acide aminophénylpropanoïque |
EP1731505B1 (fr) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Dérivés de l'acide alkoxyphénylpropanoïque |
WO2005108370A1 (fr) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | Composés du benzène |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
EP2308839B1 (fr) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques condensés |
GB0511851D0 (en) * | 2005-06-11 | 2005-07-20 | Astrazeneca Ab | Chemical compounds |
JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
WO2007013694A1 (fr) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Composé de l’acide phénoxyalkanoique |
RU2008108984A (ru) | 2005-08-10 | 2009-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Терапевтический агент от диабета |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
WO2007071966A1 (fr) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido-[4,5-b]-oxazines pour utilisation en tant qu'inhibiteurs de dgat |
JP5291471B2 (ja) * | 2006-02-15 | 2013-09-18 | アボット・ラボラトリーズ | 新規なアセチル−CoAカルボキシラーゼ(ACC)阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
CN103070854A (zh) | 2006-06-27 | 2013-05-01 | 武田药品工业株式会社 | 稠环化合物 |
WO2008047821A1 (fr) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné |
MY158052A (en) | 2006-10-19 | 2016-08-30 | Takeda Pharmaceutical | Indole compound |
JP2008179621A (ja) * | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
JPWO2008090944A1 (ja) | 2007-01-25 | 2010-05-20 | 武田薬品工業株式会社 | スピロ環化合物 |
JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
JP2010517935A (ja) | 2007-02-09 | 2010-05-27 | 武田薬品工業株式会社 | Ppar−ガンマのパーシャルアゴニストとしての縮合環化合物 |
JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
WO2008156757A1 (fr) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Composés d'indazole permettant d'activer la glucokinase |
NZ587096A (en) | 2008-03-26 | 2011-11-25 | Global Alliance For Tb Drug Dev | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
US8815876B2 (en) | 2008-07-16 | 2014-08-26 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
EP2351743A4 (fr) * | 2008-10-27 | 2012-05-09 | Takeda Pharmaceutical | Composé bicyclique |
JP2010102718A (ja) | 2009-11-27 | 2010-05-06 | Toshiba Corp | 情報処理装置 |
PE20140161A1 (es) | 2010-11-30 | 2014-02-19 | Takeda Pharmaceutical | Compuesto biciclico |
WO2012108478A1 (fr) | 2011-02-09 | 2012-08-16 | 武田薬品工業株式会社 | Composé monocyclique |
-
2011
- 2011-04-26 EP EP11722184.6A patent/EP2563765B1/fr active Active
- 2011-04-26 MA MA35387A patent/MA34245B1/fr unknown
- 2011-04-26 BR BR112012027648A patent/BR112012027648A2/pt not_active IP Right Cessation
- 2011-04-26 CA CA2797767A patent/CA2797767A1/fr not_active Abandoned
- 2011-04-26 KR KR1020127030925A patent/KR20130094211A/ko not_active Application Discontinuation
- 2011-04-26 AU AU2011246004A patent/AU2011246004A1/en not_active Abandoned
- 2011-04-26 NZ NZ603777A patent/NZ603777A/xx not_active IP Right Cessation
- 2011-04-26 EA EA201291115A patent/EA021698B1/ru not_active IP Right Cessation
- 2011-04-26 UA UAA201213528A patent/UA108102C2/ru unknown
- 2011-04-26 TW TW100114410A patent/TW201206911A/zh unknown
- 2011-04-26 GE GEAP201112904A patent/GEP20146178B/en unknown
- 2011-04-26 SG SG2012086880A patent/SG185759A1/en unknown
- 2011-04-26 UY UY0001033354A patent/UY33354A/es not_active Application Discontinuation
- 2011-04-26 WO PCT/JP2011/060616 patent/WO2011136385A1/fr active Application Filing
- 2011-04-26 AR ARP110101434A patent/AR080969A1/es unknown
- 2011-04-26 JP JP2012547392A patent/JP5693611B2/ja not_active Expired - Fee Related
- 2011-04-26 CN CN201180031899.8A patent/CN103025716B/zh not_active Expired - Fee Related
- 2011-04-26 ES ES11722184.6T patent/ES2546130T3/es active Active
- 2011-04-26 US US13/094,015 patent/US8703758B2/en not_active Expired - Fee Related
-
2012
- 2012-11-26 CR CR20120598A patent/CR20120598A/es not_active Application Discontinuation
- 2012-11-26 ZA ZA2012/08895A patent/ZA201208895B/en unknown
- 2012-11-27 CO CO12214563A patent/CO6640253A2/es active IP Right Grant
- 2012-11-27 EC ECSP12012311 patent/ECSP12012311A/es unknown
Also Published As
Publication number | Publication date |
---|---|
NZ603777A (en) | 2013-08-30 |
CA2797767A1 (fr) | 2011-11-03 |
ES2546130T3 (es) | 2015-09-18 |
ECSP12012311A (es) | 2013-05-31 |
SG185759A1 (en) | 2012-12-28 |
JP5693611B2 (ja) | 2015-04-01 |
TW201206911A (en) | 2012-02-16 |
AR080969A1 (es) | 2012-05-23 |
CO6640253A2 (es) | 2013-03-22 |
US8703758B2 (en) | 2014-04-22 |
AU2011246004A1 (en) | 2012-11-29 |
CR20120598A (es) | 2013-02-19 |
GEP20146178B (en) | 2014-10-10 |
CN103025716A (zh) | 2013-04-03 |
WO2011136385A1 (fr) | 2011-11-03 |
JP2013525262A (ja) | 2013-06-20 |
EP2563765B1 (fr) | 2015-05-27 |
EP2563765A1 (fr) | 2013-03-06 |
EA021698B1 (ru) | 2015-08-31 |
ZA201208895B (en) | 2014-01-29 |
US20110263562A1 (en) | 2011-10-27 |
UA108102C2 (uk) | 2015-03-25 |
UY33354A (es) | 2011-12-01 |
EA201291115A1 (ru) | 2013-04-30 |
CN103025716B (zh) | 2014-12-24 |
KR20130094211A (ko) | 2013-08-23 |
BR112012027648A2 (pt) | 2019-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34245B1 (fr) | Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc. | |
MA34713B1 (fr) | Compose bicyclique | |
MA32283B1 (fr) | Composes cycliques condenses et utilisation de ceux-ci | |
MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
MA30890B1 (fr) | Compose indole | |
NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
MA39069B1 (fr) | Dérivé d'urée ou sel pharmacologiquement acceptable de celui-ci | |
MA39247B1 (fr) | 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque | |
MA30421B1 (fr) | Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1 | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA30686B1 (fr) | Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase. | |
EA201000751A1 (ru) | Производные 7-азаиндола в качестве селективных ингибиторов 11-бэта-гидроксистероида дегидрогеназа 1 типа | |
WO2009121939A3 (fr) | Composés c-aryl glycosides pour le traitement du diabète et de l'obésité | |
ATE399546T1 (de) | Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 | |
MA33904B1 (fr) | Utilisation d'un agent de modification d'hormones surrénaliennes | |
ATE401073T1 (de) | Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 | |
CA2880178C (fr) | Compose de difluoromethylene | |
MA33280B1 (fr) | Preparation solide | |
MY181731A (en) | Azole benzene derivative | |
NO20071222L (no) | Benzamidforbindelser. | |
MA44021B1 (fr) | Composés antitumoraux | |
MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
NO20070789L (no) | Nikotinreseptoragonister for behandling av betennelsessykdommer | |
MA39688A (fr) | Composés hétéroaryle pour le traitement de maladies ophtalmiques | |
MA34556B1 (fr) | Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger |